Precision Business Insights
Portfolio

 

Research Reports

Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment

 

Overview:

Juvenile Idiopathic Arthritis is a most common arthritis in children. It is the inflammation of one or more joints. JIA is more common in girls. There are six different types of JIA, the symptoms may vary from type to type. Most common symptoms and signs include painful and swollen joints, stiffness in joints, joints becomes warm to touch, tiredness, relapsing fever, appearance of limp.

JIA may occur because of immune system attacks or certain gene mutations. JIA is diagnosed by blood tests for Cycliccitrullinated peptide (CCP), Anti-nuclear antibody, C-reactive protein, Rheumatoid factoretc and also by CT-Scan and MRI scan. Treatment for JIA includes NSAID’S, DMARD’s (Disease-modifying antirheumatic drugs), Biologics and corticosteroids, if the condition get worsen then surgery is recommended.

 

Segmentation:

By Trial Phase, Juvenile Idiopathic Arthritis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Juvenile Idiopathic Arthritis pipeline drugs are segmented as:

  • Novartis
  • Sanofi
  • RegeneronPharmaceuticals
  • medac GmbH
  • UCB BIOSCIENCES GmbH
  • F Hoffmann-La Roche
  • Pfizer
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Abbott Laboratories
  • Others

By Drugs, Juvenile Idiopathic Arthritis pipeline drugs are segmented as:

  • Sarlumab
  • Abatacept
  • CertolizumabPegol
  • Adalimumab
  • Tocilizumab
  • Canakinumab
  • Tofacitinib
  • Others

By Type of Condition Juvenile Idiopathic Arthritis pipeline drugs are segmented as:

  • Systemic JIA
  • Oligoarthritis
  • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
  • Psoriatic arthritis
  • Enthesitis-related arthritis
  • Undifferentiated arthritis

By Route of Administration, Juvenile Idiopathic Arthritis pipeline drugs are segmented as:

  • Oral
  • Parenteral

 

Space Analysis:

  • InNovember 2014, Novartis Pharmaceuticals commenced Phase III an open-label canakinumab (acz885) dose reduction or dose interval prolongation efficacy and safety study in patients with systemic juvenile idiopathic arthritis
  • In 22013, Pfizer commenced a long-term, phase 2/3 open-label follow-up study of tofacitinib for treatment of juvenile idiopathic arthritis

 

Report Description:

Juvenile Idiopathic Arthritis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Juvenile Idiopathic Arthritis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Juvenile Idiopathic Arthritis disease pipeline drugs development. This report studies the dynamics of the Juvenile Idiopathic Arthritis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Juvenile Idiopathic Arthritis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

  • Novartis
  • Sanofi
  • RegeneronPharmaceuticals
  • medac GmbH
  • UCB BIOSCIENCES GmbH
  • F Hoffmann-La Roche
  • Pfizer
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Abbott Laboratories

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Contact SalesTOLL FREE: +1-866-598-1553